news
Telehealth company LifeMD accused of risky GLP-1 prescribing
Former employees of telehealth provider LifeMD claim the company pressured clinicians to quickly prescribe weight loss drugs, including GLP-1s, without proper screening or follow-up. This raises concerns about patient safety and the responsible rollout of high-demand medications. Novo Nordisk previously touted LifeMD as a partner.
Former employees of telehealth provider LifeMD claim the company pressured clinicians to quickly prescribe weight loss drugs, including GLP-1s, without proper screening or follow-up. This raises concerns about patient safety and the responsible rollout of high-demand medications. Novo Nordisk previously touted LifeMD as a partner.
The architecture take
The rush to cash in on GLP-1 demand is hitting some predictable snags, like this one with LifeMD. When the incentives are skewed towards volume over patient care, you get exactly this kind of 'prescribe and pray' model. The mechanism here is clear: these are potent drugs that profoundly impact metabolism and satiety via direct gut-brain signaling. They need proper oversight. This isn't just about weight loss; it's significant physiological rewiring. For consumers, this is a loud signal: that shiny new telehealth service promising easy access might sacrifice your long-term health for speed and scale. You want a thorough workup, blood tests, and a clinician who isn't rushed. Watch for regulators to start scrutinizing these 'script mills' as the GLP-1 market matures. The industry moves fast, but the body — and its long-term health — moves on its own timeline.